An in vitro and in vivo study.
To evaluate the ability of fibrin glue to limit diffusion of recombinant human bone morphogenetic protein (rhBMP)-2 and its ability to protect spinal nerves from rhBMP-2 stimulated bone growth.
Studies have shown bone morphogenetic protein (rhBMP-2) stimulated bone growth can encroach on the spinal canal and nerves, causing neural compression. More recently, rhBMP-2 use in the cervical spine has been associated with life-threatening swelling. Fibrin glue has been used as a biologic carrier but has not been evaluated for its ability to limit rhBMP-2.
In phase 1 of the study, rhBMP-2 soaked absorbable collagen sponges (ACS) were encapsulated in fibrin glue and immediately incubated in physiologic lactated ringers solution at 38°C. Samples of solution were tested for rhBMP-2 concentration. In phase 2 of the study, rats were surgically treated with laminectomy and placement of rhBMP-2/ACS versus laminectomy and placement of fibrin glue before placement of rhBMP-2/ACS. After 8 weeks, animals were euthanized and imaged using micro-computerized tomography.
The diffusion study showed a significant limitation in rhBMP-2 diffusion when encapsulated in fibrin glue. The laminectomy study revealed blockage of bone formation by fibrin glue and protection of the spinal canal.
Fibrin glue can limit the diffusion of rhBMP-2, and, thus, it can be used to help protect the spinal canal and nerve roots from rhBMP-2 stimulated bone growth.
This study evaluates the ability of fibrin glue to limit the diffusion and bone forming effects of recombinant human bone morphogenetic protein (rhBMP)-2. An in vitro experiment encapsulating rhBMP-2 in fibrin glue showed that fibrin glue can slow the release of rhBMP-2, while an animal study showed that it can also protect the spinal canal and nerve roots from excessive bone growth.
From the *The Spine Institute at St. John’s Hospital, Santa Monica, CA, and †The Spine Center at the University of Colorado Health Sciences, Denver, CO.
Acknowledgment date: March 28, 2005. First revision date: April 21, 2005. Second revision date: June 2, 2005. Third revision date: June 23, 2005. Acceptance date: June 27, 2005.
The device(s)/drug(s) is/are FDA-approved or approved by corresponding national agency for this indication. Institutional funds were received in support of this work.
No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.
Address correspondence and reprint requests to Vikas V. Patel, MA, MD, Assistant Professor Orthopaedic and Spine Surgery, University of Colorado Health Sciences, P.O. Box 6508, Mail Stop F476, Aurora, CO 80045; E-mail: email@example.com